Identification of ZYG11A as a candidate IGF1-dependent protooncogene in endometrial cancer

Laris Achlaug, Rive Sarfstein, Karthik Nagaraj, Lena Lapkina-Gendler, Ilan Bruchim, Manisha Dixit, Zvi Laron, Shoshana Yakar, Haim Werner

Research output: Contribution to journalArticle

Abstract

The insulin-like growth factors (IGF) have a key role in the development of gynecological cancers, including endometrial tumors. Uterine serous carcinoma (USC) constitutes a defined histological category among endometrial cancers. Laron syndrome (LS) is a genetic type of dwarfism that results from mutation of the growth hormone receptor (GHR) gene, and is the best characterized entity under the spectrum of the congenital IGF1 deficiencies. Epidemiological studies have shown that LS patients are protected from cancer development. Recent genome-wide association studies conducted on LS-derived lymphoblastoid cells led to the identification of a series of metabolic genes whose over-representation in this condition might be linked to cancer protection. Our analyses led to the identification of ZYG11A, a potential cell cycle regulator, as a new downstream target for IGF1 action. The aim of the present paper was to investigate the regulation of ZYG11A gene expression by IGF1 and insulin in endometrial cancer cell lines and to assess the impact of tumor suppressor p53 on ZYG11A expression and biological action. Using USC-derived cell lines expressing a wild type or a mutant p53 gene, we demonstrate that IGF1 inhibited ZYG11A mRNA and protein levels in cells containing a wild type p53. On the other hand, IGF1 potently stimulated ZYG11A expression in mutant p53-expressing cells. Data presented here links the IGF1 and p53 signaling pathways with ZYG11A action. The clinical implications of the present study in endometrial and other types of cancer must be further investigated.

Original languageEnglish (US)
Pages (from-to)4437-4448
Number of pages12
JournalOncotarget
Volume10
Issue number43
StatePublished - Jul 1 2019

Fingerprint

Laron Syndrome
Endometrial Neoplasms
Neoplasms
Carcinoma
Somatotropin Receptors
Dwarfism
Cell Line
Genome-Wide Association Study
p53 Genes
Gene Expression Regulation
Somatomedins
Genes
Epidemiologic Studies
Cell Cycle
Insulin
Messenger RNA
Mutation
Proteins

Keywords

  • Endometrial cancer
  • IGF1 receptor
  • Insulin-like growth factor-1 (IGF1)
  • P53
  • ZYG11A

ASJC Scopus subject areas

  • Oncology

Cite this

Achlaug, L., Sarfstein, R., Nagaraj, K., Lapkina-Gendler, L., Bruchim, I., Dixit, M., ... Werner, H. (2019). Identification of ZYG11A as a candidate IGF1-dependent protooncogene in endometrial cancer. Oncotarget, 10(43), 4437-4448.

Identification of ZYG11A as a candidate IGF1-dependent protooncogene in endometrial cancer. / Achlaug, Laris; Sarfstein, Rive; Nagaraj, Karthik; Lapkina-Gendler, Lena; Bruchim, Ilan; Dixit, Manisha; Laron, Zvi; Yakar, Shoshana; Werner, Haim.

In: Oncotarget, Vol. 10, No. 43, 01.07.2019, p. 4437-4448.

Research output: Contribution to journalArticle

Achlaug, L, Sarfstein, R, Nagaraj, K, Lapkina-Gendler, L, Bruchim, I, Dixit, M, Laron, Z, Yakar, S & Werner, H 2019, 'Identification of ZYG11A as a candidate IGF1-dependent protooncogene in endometrial cancer', Oncotarget, vol. 10, no. 43, pp. 4437-4448.
Achlaug L, Sarfstein R, Nagaraj K, Lapkina-Gendler L, Bruchim I, Dixit M et al. Identification of ZYG11A as a candidate IGF1-dependent protooncogene in endometrial cancer. Oncotarget. 2019 Jul 1;10(43):4437-4448.
Achlaug, Laris ; Sarfstein, Rive ; Nagaraj, Karthik ; Lapkina-Gendler, Lena ; Bruchim, Ilan ; Dixit, Manisha ; Laron, Zvi ; Yakar, Shoshana ; Werner, Haim. / Identification of ZYG11A as a candidate IGF1-dependent protooncogene in endometrial cancer. In: Oncotarget. 2019 ; Vol. 10, No. 43. pp. 4437-4448.
@article{9fc6531b4c8f4174947d778fb2d41b74,
title = "Identification of ZYG11A as a candidate IGF1-dependent protooncogene in endometrial cancer",
abstract = "The insulin-like growth factors (IGF) have a key role in the development of gynecological cancers, including endometrial tumors. Uterine serous carcinoma (USC) constitutes a defined histological category among endometrial cancers. Laron syndrome (LS) is a genetic type of dwarfism that results from mutation of the growth hormone receptor (GHR) gene, and is the best characterized entity under the spectrum of the congenital IGF1 deficiencies. Epidemiological studies have shown that LS patients are protected from cancer development. Recent genome-wide association studies conducted on LS-derived lymphoblastoid cells led to the identification of a series of metabolic genes whose over-representation in this condition might be linked to cancer protection. Our analyses led to the identification of ZYG11A, a potential cell cycle regulator, as a new downstream target for IGF1 action. The aim of the present paper was to investigate the regulation of ZYG11A gene expression by IGF1 and insulin in endometrial cancer cell lines and to assess the impact of tumor suppressor p53 on ZYG11A expression and biological action. Using USC-derived cell lines expressing a wild type or a mutant p53 gene, we demonstrate that IGF1 inhibited ZYG11A mRNA and protein levels in cells containing a wild type p53. On the other hand, IGF1 potently stimulated ZYG11A expression in mutant p53-expressing cells. Data presented here links the IGF1 and p53 signaling pathways with ZYG11A action. The clinical implications of the present study in endometrial and other types of cancer must be further investigated.",
keywords = "Endometrial cancer, IGF1 receptor, Insulin-like growth factor-1 (IGF1), P53, ZYG11A",
author = "Laris Achlaug and Rive Sarfstein and Karthik Nagaraj and Lena Lapkina-Gendler and Ilan Bruchim and Manisha Dixit and Zvi Laron and Shoshana Yakar and Haim Werner",
year = "2019",
month = "7",
day = "1",
language = "English (US)",
volume = "10",
pages = "4437--4448",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "43",

}

TY - JOUR

T1 - Identification of ZYG11A as a candidate IGF1-dependent protooncogene in endometrial cancer

AU - Achlaug, Laris

AU - Sarfstein, Rive

AU - Nagaraj, Karthik

AU - Lapkina-Gendler, Lena

AU - Bruchim, Ilan

AU - Dixit, Manisha

AU - Laron, Zvi

AU - Yakar, Shoshana

AU - Werner, Haim

PY - 2019/7/1

Y1 - 2019/7/1

N2 - The insulin-like growth factors (IGF) have a key role in the development of gynecological cancers, including endometrial tumors. Uterine serous carcinoma (USC) constitutes a defined histological category among endometrial cancers. Laron syndrome (LS) is a genetic type of dwarfism that results from mutation of the growth hormone receptor (GHR) gene, and is the best characterized entity under the spectrum of the congenital IGF1 deficiencies. Epidemiological studies have shown that LS patients are protected from cancer development. Recent genome-wide association studies conducted on LS-derived lymphoblastoid cells led to the identification of a series of metabolic genes whose over-representation in this condition might be linked to cancer protection. Our analyses led to the identification of ZYG11A, a potential cell cycle regulator, as a new downstream target for IGF1 action. The aim of the present paper was to investigate the regulation of ZYG11A gene expression by IGF1 and insulin in endometrial cancer cell lines and to assess the impact of tumor suppressor p53 on ZYG11A expression and biological action. Using USC-derived cell lines expressing a wild type or a mutant p53 gene, we demonstrate that IGF1 inhibited ZYG11A mRNA and protein levels in cells containing a wild type p53. On the other hand, IGF1 potently stimulated ZYG11A expression in mutant p53-expressing cells. Data presented here links the IGF1 and p53 signaling pathways with ZYG11A action. The clinical implications of the present study in endometrial and other types of cancer must be further investigated.

AB - The insulin-like growth factors (IGF) have a key role in the development of gynecological cancers, including endometrial tumors. Uterine serous carcinoma (USC) constitutes a defined histological category among endometrial cancers. Laron syndrome (LS) is a genetic type of dwarfism that results from mutation of the growth hormone receptor (GHR) gene, and is the best characterized entity under the spectrum of the congenital IGF1 deficiencies. Epidemiological studies have shown that LS patients are protected from cancer development. Recent genome-wide association studies conducted on LS-derived lymphoblastoid cells led to the identification of a series of metabolic genes whose over-representation in this condition might be linked to cancer protection. Our analyses led to the identification of ZYG11A, a potential cell cycle regulator, as a new downstream target for IGF1 action. The aim of the present paper was to investigate the regulation of ZYG11A gene expression by IGF1 and insulin in endometrial cancer cell lines and to assess the impact of tumor suppressor p53 on ZYG11A expression and biological action. Using USC-derived cell lines expressing a wild type or a mutant p53 gene, we demonstrate that IGF1 inhibited ZYG11A mRNA and protein levels in cells containing a wild type p53. On the other hand, IGF1 potently stimulated ZYG11A expression in mutant p53-expressing cells. Data presented here links the IGF1 and p53 signaling pathways with ZYG11A action. The clinical implications of the present study in endometrial and other types of cancer must be further investigated.

KW - Endometrial cancer

KW - IGF1 receptor

KW - Insulin-like growth factor-1 (IGF1)

KW - P53

KW - ZYG11A

UR - http://www.scopus.com/inward/record.url?scp=85069454404&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069454404&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 4437

EP - 4448

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 43

ER -